Drugs / HH-120
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05753878 | Nov 2022 → Jan 2023 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase 1 | NCT05116865 | Nov 2021 → May 2022 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05713318 | Jan → Jun 2023 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05765279 | Oct → Dec 2022 | COVID-19 | Beijing Ditan Hospital | Completed | No outcome recorded |
| — | NCT05659602 | Jul 2022 → Jan 2023 | COVID-19 | Beijing Ditan Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06039163 Comparator | Apr → Oct 2022 | COVID-19 | Huahui Health | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-28 | Huahui Health | Results HH-120, Huahui’s Investigational Full-Spectrum Anti-COVID-19 Medicine, Remains Highly Effective against Newly Emerged Variants huahuihealth.com ↗
Huahui Health, a Beijing-based, clinical stage biotechnology company focused on discovering and developing virology, hepatology and oncology therapies, today announced that its full-spectrum anti-SARS-CoV-2 drug candidate HH-120, has shown high neutralization effects against newly emerged XBB and BF.7 Omicron variants in pseudovirus studies. |
| 2021-12-13 | Huahui Health | Results Huahui’s Broad-Spectrum COVID Drug Candidate Remains Highly Effective against Omicron huahuihealth.com ↗
The results all suggest that HH-120 remains highly effective against Omicron, despite the large number of mutations on its spike protein. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-28 | Huahui Health | HH-120, Huahui’s Investigational Full-Spectrum Anti-COVID-19 Medicine, Remains Highly Effective against Newly Emerged Variants huahuihealth.com ↗ |
| 2021-12-13 | Huahui Health | Huahui’s Broad-Spectrum COVID Drug Candidate Remains Highly Effective against Omicron huahuihealth.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05713318 ↗ |
| Modality | Protein / enzyme biologic | “HH-120 is a novel inhalable biologic” NCT05116865 ↗ |
| Route | Inhaled | “HH-120 administered by aerosol inhalation” NCT05116865 ↗ |